Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Di Rocco

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Blood|December 16, 2010
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphomaDavide Rossi, Silvia Rasi, Alice Di Rocco, et al.
The Lancet. Haematology|December 9, 2016
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana LinfomiCarlo Visco, Annalisa Chiappella, Luca Nassi, et al.
British Journal of Haematology|February 3, 2023
Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana LinfomiAnnalisa Arcari, Valentina Tabanelli, Francesco Merli, et al.
Hematological Oncology|August 21, 2020
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphomaIrene Della Starza, Lucia Anna De Novi, Marzia Cavalli, et al.
American Journal of Hematology|March 5, 2019
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphomaFrancesco Maura, Luca Agnelli, Daniel Leongamornlert, et al.
Blood Advances|May 5, 2026
Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE studyGiulia Gabrielli, Beatrice Casadei, Annalisa Chiappella, et al.
Hematological Oncology|May 2, 2020
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantationAndrés J M Ferreri, Marianna Sassone, Piera Angelillo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
Hematological Oncology|October 17, 2022
Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biasesRoberta Soscia, Irene Della Starza, Lucia Anna De Novi, et al.
Blood Advances|May 12, 2023
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCLMaria Chiara Tisi, Riccardo Moia, Caterina Patti, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Blood|December 16, 2010
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphomaDavide Rossi, Silvia Rasi, Alice Di Rocco, et al.
The Lancet. Haematology|December 9, 2016
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana LinfomiCarlo Visco, Annalisa Chiappella, Luca Nassi, et al.
British Journal of Haematology|February 3, 2023
Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana LinfomiAnnalisa Arcari, Valentina Tabanelli, Francesco Merli, et al.
Hematological Oncology|August 21, 2020
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphomaIrene Della Starza, Lucia Anna De Novi, Marzia Cavalli, et al.
American Journal of Hematology|March 5, 2019
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphomaFrancesco Maura, Luca Agnelli, Daniel Leongamornlert, et al.
Blood Advances|May 5, 2026
Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE studyGiulia Gabrielli, Beatrice Casadei, Annalisa Chiappella, et al.
Hematological Oncology|May 2, 2020
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantationAndrés J M Ferreri, Marianna Sassone, Piera Angelillo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
Hematological Oncology|October 17, 2022
Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biasesRoberta Soscia, Irene Della Starza, Lucia Anna De Novi, et al.
Blood Advances|May 12, 2023
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCLMaria Chiara Tisi, Riccardo Moia, Caterina Patti, et al.
Pageof 11